SpectraCure’s current main focus are the clinical phase 2 study and the development of the new generation of SpectraCure's treatment system. The clinical trial, designated for treatment of patients with recurrent prostate cancer using the company's photodynamic therapy (PDT) technology, is ongoing at our partner hospitals. The recruitment of patients for the fall in the phase 2 study is going on continuously.
During summer, the first units of the new generation PDT system were installed and tested in SpectraCure's laboratory in Lund. The tests will continue coming weeks and at the same time the regulatory work is starting, to obtain authority approval to use the systems in clinical trials.
Hopefully,we can release the new generation PDT system to be used in the clinical trials and possibly also fast track, after the authorities approval (FDA), comments Masoud Khayyami, CEO.
During summer, work has also been done writing a patent application to protect central parts of the construction on which the new PDT system is based.
